ABT-494
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ABT-494, covering 2018-06-27 to 2023-08-14. Get the full timeline:
Most recent: Clinical Trial Update: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy [Phase 2]